<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">M. Fathi Ilmawan</style></author><author><style face="normal" font="default" size="100%">Soetjipto</style></author><author><style face="normal" font="default" size="100%">M. Guritno Suryokusumo</style></author><author><style face="normal" font="default" size="100%">M. Miftahussurur</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of Hyperbaric Oxygen Therapy on the Expression of FGF, MMP-9 and Occludin in the Repair of Gastric Mucosal Erosions</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">FGF</style></keyword><keyword><style  face="normal" font="default" size="100%">Gastric mucosal erosions</style></keyword><keyword><style  face="normal" font="default" size="100%">HBOT</style></keyword><keyword><style  face="normal" font="default" size="100%">MMP-9</style></keyword><keyword><style  face="normal" font="default" size="100%">Occludin.</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">June 2022</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">660-671</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;This study was conducted to evaluate the immunohistochemical (IHC) expression of fibroblast growth factor (FGF), matrix metalloproteinase-9 (MMP-9) and occludin in the repair of gastric mucosal erosions in Wistar rats was induced by administration of aspirin, one of the non-steroidal anti-inflammatory drugs (NSAIDs). These expressions are associated with changes in histopathological features. This experimental research used a posttest only control group design. The research sample was 28 male Wistar rats that met the inclusion criteria, but not met the exclusion criteria. The samples were randomly allocated into four groups. Group 1 as negative control and group 2 as positive control. Group 3 as treatment 1, which was given HBOT (hyperbaric oxygen therapy) 2.4 ATA for 3 x 30 minutes/day (air break 5 minutes) for 5 days, after aspirin induction at 30 mg/kgBW/day for 10 days. Group 4 as treatment 2, which was given HBOT 2.4 ATA for 3 x 30 minutes/day (air break 5 minutes) for 10 days, after aspirin induction at 30 mg/kgBW/day for 10 days. Each group was evaluated the immunohistochemical (IHC) expression of FGF, MMP-9 and occludin, using the Remmele scale index, immune reactive score (IRS). The expressions were correlated with histopathological changes, using the HAI (Histology Activity Index) method. The results show that the HBOT 2.4 ATA for 3 x 30 minutes/day (air break 5 minutes) for 5 days and for 10 days, it can improve FGF (p=0.016) and occludin (p=0.021) expression significantly. The HBOT can also reduce inflammation (p=0.005), epithelial defects (p&amp;lt;0.001) and MMP-9 expression (0.042). There is a significant difference in occludin expression (p=0.034) between 5-day HBOT and 10-day HBOT. However, there was no significant difference between the 5-day HBOT and the 10-day HBOT for reduce inflammation (p=0.845), epithelial defects (p=0.469), FGF expression (0.054) and MMP-9 expression (0.470). The provision of HBOT at 2.4 ATA significantly improved gastric mucosal erosion in NSAID-induced gastric mucosal erosion Wistar rats model, by decreasing MMP-9 expression, as well as increasing FGF and occludin expression. There is a significant difference in occludin expression between 5-day HBOT and 10-day HBOT.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><accession-num><style face="normal" font="default" size="100%">25</style></accession-num><section><style face="normal" font="default" size="100%">660</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;M. Fathi Ilmawan&lt;sup&gt;1,2&lt;/sup&gt;, Soetjipto&lt;sup&gt;3,*&lt;/sup&gt;, M. Guritno Suryokusumo&lt;sup&gt;4&lt;/sup&gt;, M. Miftahussurur&lt;sup&gt;5&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Doctoral Program of Medical Sciences, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Internal Medicine, Faculty of Medicine, Universitas Hang Tuah, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Universitas Airlangga Hospital, Surabaya; Institute of Tropical Disease, Department of Medical Biochemistry, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Department of Hyperbaric, Universitas Pembangunan Nasional, Jakarta, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;5&lt;/sup&gt;Universitas Airlangga Hospital, Surabaya; Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dharma S</style></author><author><style face="normal" font="default" size="100%">Rahmawati Y</style></author><author><style face="normal" font="default" size="100%">Nessa</style></author><author><style face="normal" font="default" size="100%">Dillasamolla S</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of Fibroblast Growth Factor Combination with Ethanol Extract of Morinda citrifolia L. on Blood Glucose Levels</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Diabetes mellitus</style></keyword><keyword><style  face="normal" font="default" size="100%">FGF</style></keyword><keyword><style  face="normal" font="default" size="100%">Morinda citrifolia</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">November 2019</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">11</style></volume><pages><style face="normal" font="default" size="100%">1558-1562</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;A research has been conducted on the effect of giving Fibroblast Growth Factor (FGF) with &lt;em&gt;Morinda citrifolia&lt;/em&gt; L. ethanol extract. This study aims to determine whether the administration of a combination of FGF with ethanol extract of noni fruit can reduce blood glucose levels in diabetes mice induced by alloxan. FGF requires amino acids in regenerating pancreatic &lt;em&gt;β&lt;/em&gt; cells, where the amino acids expected from noni fruit can provide a signal response in regenerating pancreatic &lt;em&gt;β&lt;/em&gt; cells. In addition, the active substances contained in noni fruit namely xeronine and flavonoid alkaloids can function to reduce blood glucose levels. Test animals were divided into 6 groups, each group consisted of 10 male white mice. Group 1 is a normal control group is a group without any given. Group 2 was a negative control group given 150 mg/kg alloxan. Group 3, 4, and 5 are the treatment groups that are given alloxan and the combination of noni fruit ethanol extract with 3 variations of dose (125; 350; and 1000) mg / KgBW plus FGF dose of 800 mg / kgBW, group 6 is the comparison which is only given FGF alone at a dose of 800 mg / kgBW. The study was conducted for 21 days, observed every 7&lt;sup&gt;th&lt;/sup&gt;, 14&lt;sup&gt;th&lt;/sup&gt;, 21&lt;sup&gt;st &lt;/sup&gt;day using the Easy Touch&lt;sup&gt;®&amp;nbsp;&lt;/sup&gt;GCU digital device. The results of this study showed that administration of noni fruit ethanol extract with FGF was able to reduce blood glucose levels by significance (&lt;em&gt;p &lt;/em&gt;&amp;lt;0.05) and based on the percentage calculation of blood glucose levels as much as 44.9% at a dose of 1000 mg / kgBW on the day observations 21&lt;sup&gt;st&lt;/sup&gt;.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">6s</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">1558</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Dharma S&lt;sup&gt;1,&lt;/sup&gt;*, Rahmawati Y&lt;sup&gt;2&lt;/sup&gt;, Nessa&lt;sup&gt;2&lt;/sup&gt;, Dillasamolla S&lt;sup&gt;1&lt;/sup&gt; &lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Faculty of Pharmacy, Andalas University, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Indonesian Pioneer Pharmacy College, Padang, INDONESIA.&lt;/p&gt;
</style></auth-address></record></records></xml>